NCT07088458View on ClinicalTrials.gov

An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

October 1, 2029

Study Completion Date

January 1, 2030

Conditions

Hemophilia A

Interventions

DRUG

Damoctocog alfa pegol (Jivi, Bay94-9027)

Follow clinical practice of BAY94-9027 to further define the treatment outcomes of damoctocog alfa pegol based on real-world use for regular prophylaxis in ages 7 to \<12 years, including a broader population and a real-world treatment patterns.